JAZZ

#708
Jazz Pharmaceuticals, Inc.
190.0200
-0.12%
Sector:
Básica:
Profit Currency:
Rango diario
190.0200
190.0200
Rango anual
128.8000
197.6000
Cambio diario
-0.12%
Monthly Change
+13.55%
6 month change
+35.73%
Cambio anual
+35.73%
Cierres anteriores
190.2500
Open
190.0200
Bid
Ask
Low
190.0200
High
190.0200
Volumen
98
Open full chart

Financials

Overview Statement Statistics Dividends
Quarterly Annual
  • Market Capitalization 11.5876 B
  • Employee 2 800
  • Founded 2003
  • CEO Bruce C Cozadd
  • Website www.jazzpharmaceuticals.com
  • Headquarter Ireland
  • FIGI N/A
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-29.11
Price to sales ratio
2.43
Dividends per share
—
Dividend yield %
—

Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals. In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use. The company is also a member of the Pharmaceutical Research and Manufacturers of America.

Noticias